Phibro Animal Health Corp. announced July 8 that it is pursuing patent protection following a "significant advance in the ongoing development of a vaccine for African swine fever (ASF)."
According to the announcement, this important step in the vaccine development process involves the identification of immunogenic epitopes and proteins that show strong potential to form the basis for a vaccine against ASF.
Phibro said its research and development team and collaborators made this identification through the use of a unique bioinformatics analysis tool in order to select for the highest-potential epitopes and proteins capable of eliciting protective immune response.
Phibro’s approach is to create a specific epitope-based vaccine, rather than following the more conventional path of an attenuated live vaccine, the company said in its announcement. If successful, this approach would not only be an effective response to ASF but would result in a vaccine that presents no risk of further spreading the disease, the company said.
Phibro chairman, president and chief executive officer Jack Bendheim said, “ASF’s decimation of China’s swine population represents not just a crisis for the entire swine husbandry industry but, more importantly, a food security crisis for mankind. The identification of this group of peptides and proteins is a key milestone in Phibro’s pursuit of a solution for this devastating disease. While we still have much work ahead of us, we have made important progress toward reaching that goal, and we take pride in potentially being part of the solution to such an urgent problem.”
Phibro Animal Health is a diversified global developer, manufacturer and supplier of a broad range of animal health and mineral nutrition products for livestock, helping veterinarians and farmers produce healthy, affordable food while using fewer natural resources.